Montreal and Charlotte, NC, May 8, 2019 — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular...
Turner will provide his perspective on adopting personalized medicine and the potential ROI at the Duke Center for Personalized Medicine Symposium on March 29 in Durham, NC.
News | 03. 28. 2012
Turner will provide his perspective on adopting personalized medicine and the potential ROI at the Duke Center for Personalized Medicine Symposium on March 29 in Durham, NC.
